- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03394677
Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis
Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerabililty of RVT-501 Topical Ointment in Pediatric Patients With Mild to Moderate Atopic Dermatitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Dermavant Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2K 4L5
- Dermavant Investigational Site
-
-
-
-
California
-
Los Angeles, California, United States, 90045
- Dermavant Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73118
- Dermavant Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97223
- Dermavant Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75230
- Dermavant Investigational Site
-
San Antonio, Texas, United States, 78213
- Dermavant Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female pediatric patients ages 2-17 years of age with confirmed diagnosis of atopic dermatitis by Hanifin and Rajka criteria [Hanifin, 1980].
Patients with atopic dermatitis covering 5% to 40% of the body surface area (BSA) and with an Investigator Global Assessment (IGA) of 2 or 3 (mild or moderate atopic dermatitis) at Baseline. Scalp, palms, and soles should be excluded from the BSA calculation to determine eligibility at Baseline.
Note: Patients with mild disease (IGA = 2) will be limited to approximately 25% of total enrollment.
Females of childbearing potential and male patients who are engaging in sexual activity that could lead to pregnancy must use the following adequate birth control methods while on study and for 2 weeks after stopping the study drug. Acceptable contraception methods are:
- Male or male partner with vasectomy, OR
- Male condom AND partner use of one of the contraceptive options below:
- Spermicide;
- Contraceptive subdermal implant that meets effectiveness criteria including a <1% rate of failure per year, as stated in the product label;
- Intrauterine device or intrauterine system that meets effectiveness criteria including <1% rate of failure per year, as stated in the product label;
- Oral contraceptive, either combined or progestogen alone;
- Injectable progestogen;
- Contraceptive vaginal ring;
- Percutaneous contraceptive patches.
These allowed methods of contraception are only effective when used consistently, correctly, and in accordance with the product label. The Investigator is responsible for ensuring that patients understand how to properly use these methods of contraception.
Non-child-bearing potential is defined as pre-menarchal or pre-menopausal females with a documented bilateral tubal ligation, bilateral oophorectomy (removal of the ovaries) or hysterectomy, or hysteroscopic sterilization. Documented verbal history from the patient is acceptable.
Patients who are abstinent are eligible, but they must agree to use of one of the birth control methods listed above if they start engaging in sexual activity that could lead to pregnancy during the study.
Female subjects of childbearing potential must have a negative pregnancy test at Screening and Baseline (Day 0).
- History of atopic dermatitis and stable disease for at least 1 month according to the patient/caregiver.
- Patient, patient's parent(s), or legal representative must be capable of giving written informed consent or verbal assent, as applicable, which includes compliance with the requirements and restrictions listed in the consent/assent form; written informed consent must be obtained prior to any study related procedures.
Exclusion Criteria:
- A positive Hepatitis B surface antigen (HBsAg) or positive Hepatitis C antibody result, or positive human immunodeficiency virus (HIV) antibody at Screening.
- Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5x the upper limit of normal (ULN).
- Screening total bilirubin > 1.5x ULN; total bilirubin > ULN and ≤ 1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%.
- Patients with a skin condition such as Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impetigo, psoriasis, severe acne, connective tissue disorder, or Netherton's syndrome, or any other disease that could impact study evaluations.
Use of any prohibited medication.
Prohibited concomitant medications, therapy, etc. during the defined period are as listed in the bullets below. If a patient requires any of these medications throughout the study period, he/she may be excluded from or discontinued from the study, at the discretion of the Investigator and medical monitor.
- From 6 months prior to the first application of study drugs to the completion of the
Follow-up visit or discontinuation:
- Biological products that might have significantly affected the evaluation of atopic dermatitis condition (e.g., tumor necrosis factor [TNF] inhibitors, anti- immunoglobulin [Ig]E antibodies, anti-CD20 antibodies, anti-interleukin [IL]-4 receptor).
- From 28 days prior to the first application of study drug until the completion of the Follow- up visit or discontinuation:
- Corticosteroid preparations (oral, injection, and suppository preparations) and topical corticosteroids that were classified as super-high potency (clobetasol propionate). Eye drop and nasal preparations are allowed. Inhaled preparations are allowed if used for a stable condition and at a stable dose for > 28 days before Screening, and are continued at the same dose throughout the study.
- Oral preparations and injections of immunosuppressants (cyclosporine, methotrexate, azathioprine, tacrolimus, etc.);
- Excessive sun exposure, tanning booth, other ultraviolet (UV) light source and phototherapy including psoralen and ultraviolet A (PUVA) therapy.
- From 14 days prior to the first application of the study drug to the completion of the
Follow-up visit or discontinuation:
- Herbal medicines for atopic dermatitis (topical and oral preparations), unless specifically approved by the sponsor;
- Eucrisa™ (crisaborole) and any other topical phosphodiesterase 4 (PDE4) inhibitor;
- Tacrolimus and pimecrolimus cream and/or ointment;
- Topical corticosteroids that were classified as low, medium, or high potency (fluocinonide, triamcinolone acetonide, desonide, hydrocortisone). Eye drops and nasal preparations are allowed.
- From 7 days prior to the first application of the study drug to the completion of the
Follow-up visit or discontinuation:
- Oral or intravenous antibiotics, antifungal or antivirus medications
- Antihistamines/anti-allergics (oral, topical and injections): diphenhydramine, chlorpheniramine maleate, hydroxyzine).
NOTE: The following antihistamines are allowed:
- Loratadine, fexofenadine hydrochloride, cetirizine hydrochloride
- Pregnant or lactating females.
- History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or medical monitor, contraindicates their participation.
- The patient has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).
- Current or a history of cancer within 5 years.
- Patients with active infection in atopic dermatitis areas requiring antibiotics, antifungals, or antiviral agents within 7 days of Baseline (Day 0).
- Patients with pruritus due to conditions other than atopic dermatitis that, in the opinion of the Investigator, would either interfere with study evaluations or affect the safety of the patient.
- Patients with advanced disease or recent abnormal laboratory test values that could affect the safety of the patient or the implementation of this study, as determined by medical records.
- History of and/or concurrent condition of serious hypersensitivity (anaphylactic shock or anaphylactoid reaction) to PDE4 inhibitors.
- Prior exposure to RVT-501.
- Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular system abnormalities or laboratory abnormalities that will affect the health of the patient or interfere with interpretation of the results.
- The patient has excessive sun exposure, is planning a trip to a sunny climate that would involve excessive sun exposure, or used tanning booths within 28 days prior to Baseline (Day 0) or is not willing to minimize natural and artificial sunlight exposure during the study.
Other Eligibility Criteria Considerations:
To assess any potential impact on patient eligibility with regard to safety, the Investigator must refer to the following document for detailed information regarding warnings, precaustions, contraindications, adverse events, and other significant data pertaining to the investigational product being used in the study:
- The current version of the RVT-501 Investigator's Brochure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RVT-501 0.5% ointment
Subjects will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
|
Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
|
Placebo Comparator: RVT-501 vehicle ointment
Subjects will receive RVT-501 vehicle ointment twice daily (BID) for 4 weeks.
|
Placebo comparator - ointment twice daily (BID) for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy - Investigator Global Assessment (IGA) score
Time Frame: 28 days
|
Efficacy will be assessed by determining the proportion of patients who achieve an Investigator Global Assessment (IGA) score of 0 or 1 and at least a 2-point improvement in IGA at Week 4. The IGA will be assessed at every study visit.
The IGA is a 5-point morphological assessment of overall disease severity and will be determined according to the following categories: 0-clear; 1-almost clear; 2-mild disease; 3-moderate disease; 4-severe disease.
|
28 days
|
Efficacy - Eczema Area Severity Index (EASI) score
Time Frame: 28 days
|
Efficacy will be assessed by determining the proportion of patients who achieve a 50% reduction in Eczema Area Severity Index score (EASI-50) at Week 4.The EASI will be assessed at every study visit.
It quantifies the severity of a patient's atopic dermatitis based on both lesion severity and the percent of body surface area affected.
The EASI is a composite score ranging from 0-72 that takes into account the degree of erythema, induration/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region relative to the whole body.
|
28 days
|
Efficacy - Peak Pruritus Numeric Rating Scale (NRS)
Time Frame: 28 days
|
Efficacy will be assessed as change from Baseline to Week 4 in peak pruritus as measured with the 24-hour Peak Pruritus Numeric Rating Scale (NRS).
Peak Pruitus NRS will be measured at each visit.
The assessment consists of a patient-rated scale of 0-10, where 0 is "No itch" and 10 is the "Worst itch possible."
|
28 days
|
Efficacy - Whole body surface area (BSA) affected
Time Frame: 28 days
|
This exploratory endpoint will be evaluated as the change in total score from Baseline at all visits in whole body BSA (body surface area) affected.
Whole body BSA affected will be assessed at every visit.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and severity of adverse events (local and systemic)
Time Frame: 28 days
|
Adverse events will be coded using the most current release of MedDRA® (Medical Dictionary for Regulatory Activities).
The number and proportion of subjects with adverse events will be summarized by treatment, system organ class, and preferred term for all adverse events, all adverse events considered by the investigator to be related to study drug, all serious adverse events, and all adverse events leading to study drug discontinuation
|
28 days
|
Plasma concentrations of RVT-501
Time Frame: 7 days
|
PK samples will be collected only at the Week 1 visit in 2-11 year old patients.
RVT-501 will be measured in plasma by validated assay to confirm exposure.These plasma concentrations will be listed by metabolite, subject, treatment, and time; and will be summarized by analyte and time.
|
7 days
|
Plasma concentrations of M11 metabolite
Time Frame: 7 days
|
PK samples will be collected only at the Week 1 visit in 2-11 year old patients.
The M11 metabolite will be measured in plasma by validated assay to confirm exposure.
These plasma concentrations will be listed by metabolite, subject, treatment, and time; and will be summarized by metabolite, treatment and time.
|
7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: James Lee, MD, PhD, Dermavant Sciences, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RVT-501-2004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on RVT-501 0.5% ointment
-
Dermavant Sciences GmbHCompletedAtopic DermatitisCanada, United States
-
Dermavant Sciences GmbHUnknownAtopic DermatitisUnited States
-
PfizerCompletedDermatitis, AtopicAustralia, United States
-
Reistone Biopharma Company LimitedActive, not recruiting
-
Chong Kun Dang PharmaceuticalUnknownT2DM (Type 2 Diabetes Mellitus)Korea, Republic of
-
Bausch & Lomb IncorporatedCompletedOcular InflammationUnited States
-
Assiut UniversityNot yet recruitingChronic Sinusitis | Nasal Polyps
-
Azura OphthalmicsORA, Inc.Not yet recruitingDry Eye DiseaseUnited States
-
Chong Kun Dang PharmaceuticalCompletedHealthy Male VolunteerKorea, Republic of
-
Koffler Vision GroupFera Pharmaceuticals, LLCTerminatedAllergic ConjunctivitisUnited States